[
  {
    "title": "Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit",
    "published": 1740744070,
    "day_prices": {
      "2025-02-28T14:30:00+00:00": 701.3200073242188,
      "2025-02-28T15:30:00+00:00": 695.6199951171875,
      "2025-02-28T16:30:00+00:00": 695.010009765625,
      "2025-02-28T17:30:00+00:00": 699.9130249023438,
      "2025-02-28T18:30:00+00:00": 697.4249877929688,
      "2025-02-28T19:30:00+00:00": 695.1099853515625,
      "2025-02-28T20:30:00+00:00": 698.7750244140625
    },
    "sentiment": 0.7298121452331543
  },
  {
    "title": "Regeneron Gets CHMP Backing of Linvoseltamab in Multiple Myeloma",
    "published": 1740729014,
    "day_prices": {
      "2025-02-28T14:30:00+00:00": 701.3200073242188,
      "2025-02-28T15:30:00+00:00": 695.6199951171875,
      "2025-02-28T16:30:00+00:00": 695.010009765625,
      "2025-02-28T17:30:00+00:00": 699.9130249023438,
      "2025-02-28T18:30:00+00:00": 697.4249877929688,
      "2025-02-28T19:30:00+00:00": 695.1099853515625,
      "2025-02-28T20:30:00+00:00": 698.7750244140625
    },
    "sentiment": 0.6907215714454651
  },
  {
    "title": "Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN",
    "published": 1740721580,
    "day_prices": {
      "2025-02-28T14:30:00+00:00": 701.3200073242188,
      "2025-02-28T15:30:00+00:00": 695.6199951171875,
      "2025-02-28T16:30:00+00:00": 695.010009765625,
      "2025-02-28T17:30:00+00:00": 699.9130249023438,
      "2025-02-28T18:30:00+00:00": 697.4249877929688,
      "2025-02-28T19:30:00+00:00": 695.1099853515625,
      "2025-02-28T20:30:00+00:00": 698.7750244140625
    },
    "sentiment": 0.7714900374412537
  },
  {
    "title": "First Circuit Adopts \"But For\" Causation Standard Under The Anti-Kickback Statute, Paving The Way For Potential Supreme Court Review",
    "published": 1740712214,
    "day_prices": {
      "2025-02-28T14:30:00+00:00": 701.3200073242188,
      "2025-02-28T15:30:00+00:00": 695.6199951171875,
      "2025-02-28T16:30:00+00:00": 695.010009765625,
      "2025-02-28T17:30:00+00:00": 699.9130249023438,
      "2025-02-28T18:30:00+00:00": 697.4249877929688,
      "2025-02-28T19:30:00+00:00": 695.1099853515625,
      "2025-02-28T20:30:00+00:00": 698.7750244140625
    },
    "sentiment": 0.700007438659668
  },
  {
    "title": "Regeneron makes second bid for blood cancer therapy approval",
    "published": 1740658663,
    "day_prices": {
      "2025-02-27T14:30:00+00:00": 705.9000244140625,
      "2025-02-27T15:30:00+00:00": 717.5239868164062,
      "2025-02-27T16:30:00+00:00": 713.8400268554688,
      "2025-02-27T17:30:00+00:00": 711.719970703125,
      "2025-02-27T18:30:00+00:00": 709.2999877929688,
      "2025-02-27T19:30:00+00:00": 708.0800170898438,
      "2025-02-27T20:30:00+00:00": 704.2000122070312
    },
    "sentiment": 0.5519335269927979
  },
  {
    "title": "Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day",
    "published": 1740588060,
    "day_prices": {
      "2025-02-26T14:30:00+00:00": 721.2899780273438,
      "2025-02-26T15:30:00+00:00": 714.4749755859375,
      "2025-02-26T16:30:00+00:00": 711.0499877929688,
      "2025-02-26T17:30:00+00:00": 709.6900024414062,
      "2025-02-26T18:30:00+00:00": 702.2550048828125,
      "2025-02-26T19:30:00+00:00": 708.1699829101562,
      "2025-02-26T20:30:00+00:00": 706.0599975585938
    },
    "sentiment": 0.939586877822876
  },
  {
    "title": "Merck's Oncology Strength: Beating Wall Street Again",
    "published": 1740561344,
    "day_prices": {
      "2025-02-26T14:30:00+00:00": 721.2899780273438,
      "2025-02-26T15:30:00+00:00": 714.4749755859375,
      "2025-02-26T16:30:00+00:00": 711.0499877929688,
      "2025-02-26T17:30:00+00:00": 709.6900024414062,
      "2025-02-26T18:30:00+00:00": 702.2550048828125,
      "2025-02-26T19:30:00+00:00": 708.1699829101562,
      "2025-02-26T20:30:00+00:00": 706.0599975585938
    },
    "sentiment": 0.8620699644088745
  },
  {
    "title": "Regeneron: FDA Accepts Odronextamab Lymphoma Drug Resubmission",
    "published": 1740555780,
    "day_prices": {
      "2025-02-26T14:30:00+00:00": 721.2899780273438,
      "2025-02-26T15:30:00+00:00": 714.4749755859375,
      "2025-02-26T16:30:00+00:00": 711.0499877929688,
      "2025-02-26T17:30:00+00:00": 709.6900024414062,
      "2025-02-26T18:30:00+00:00": 702.2550048828125,
      "2025-02-26T19:30:00+00:00": 708.1699829101562,
      "2025-02-26T20:30:00+00:00": 706.0599975585938
    },
    "sentiment": 0.7844715118408203
  },
  {
    "title": "Regeneron Pharmaceuticals, Inc. (REGN): Among the Stocks That Will Go to The Moon According to Analysts",
    "published": 1740504371,
    "day_prices": {
      "2025-02-25T14:30:00+00:00": 719.989990234375,
      "2025-02-25T15:30:00+00:00": 733.5900268554688,
      "2025-02-25T16:30:00+00:00": 730.0499877929688,
      "2025-02-25T17:30:00+00:00": 731.3599853515625,
      "2025-02-25T18:30:00+00:00": 726.3693237304688,
      "2025-02-25T19:30:00+00:00": 720.7000122070312,
      "2025-02-25T20:30:00+00:00": 721.9249877929688
    },
    "sentiment": 0.9096256494522095
  },
  {
    "title": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains",
    "published": 1740501720,
    "day_prices": {
      "2025-02-25T14:30:00+00:00": 719.989990234375,
      "2025-02-25T15:30:00+00:00": 733.5900268554688,
      "2025-02-25T16:30:00+00:00": 730.0499877929688,
      "2025-02-25T17:30:00+00:00": 731.3599853515625,
      "2025-02-25T18:30:00+00:00": 726.3693237304688,
      "2025-02-25T19:30:00+00:00": 720.7000122070312,
      "2025-02-25T20:30:00+00:00": 721.9249877929688
    },
    "sentiment": 0.8111350536346436
  },
  {
    "title": "Big Pipeline Updates From Kiniksa Pharmaceuticals",
    "published": 1740500046,
    "day_prices": {
      "2025-02-25T14:30:00+00:00": 719.989990234375,
      "2025-02-25T15:30:00+00:00": 733.5900268554688,
      "2025-02-25T16:30:00+00:00": 730.0499877929688,
      "2025-02-25T17:30:00+00:00": 731.3599853515625,
      "2025-02-25T18:30:00+00:00": 726.3693237304688,
      "2025-02-25T19:30:00+00:00": 720.7000122070312,
      "2025-02-25T20:30:00+00:00": 721.9249877929688
    },
    "sentiment": 0.9114001393318176
  },
  {
    "title": "Levi & Korsinsky Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - REGN",
    "published": 1740462379,
    "day_prices": {
      "2025-02-25T14:30:00+00:00": 719.989990234375,
      "2025-02-25T15:30:00+00:00": 733.5900268554688,
      "2025-02-25T16:30:00+00:00": 730.0499877929688,
      "2025-02-25T17:30:00+00:00": 731.3599853515625,
      "2025-02-25T18:30:00+00:00": 726.3693237304688,
      "2025-02-25T19:30:00+00:00": 720.7000122070312,
      "2025-02-25T20:30:00+00:00": 721.9249877929688
    },
    "sentiment": 0.5482106804847717
  },
  {
    "title": "Regeneron Pharmaceuticals (REGN): Among the Best Growth Stocks to Invest In According to Analysts",
    "published": 1740419174,
    "day_prices": {
      "2025-02-24T14:30:00+00:00": 702.7050170898438,
      "2025-02-24T15:30:00+00:00": 716.0999755859375,
      "2025-02-24T16:30:00+00:00": 717.1719970703125,
      "2025-02-24T17:30:00+00:00": 715.9400024414062,
      "2025-02-24T18:30:00+00:00": 709.1998901367188,
      "2025-02-24T19:30:00+00:00": 710.6500244140625,
      "2025-02-24T20:30:00+00:00": 716.9600219726562
    },
    "sentiment": 0.8541777729988098
  },
  {
    "title": "The Zacks Analyst Blog Highlights Merck, Sanofi, Regeneron and Ionis",
    "published": 1740390360,
    "day_prices": {
      "2025-02-24T14:30:00+00:00": 702.7050170898438,
      "2025-02-24T15:30:00+00:00": 716.0999755859375,
      "2025-02-24T16:30:00+00:00": 717.1719970703125,
      "2025-02-24T17:30:00+00:00": 715.9400024414062,
      "2025-02-24T18:30:00+00:00": 709.1998901367188,
      "2025-02-24T19:30:00+00:00": 710.6500244140625,
      "2025-02-24T20:30:00+00:00": 716.9600219726562
    },
    "sentiment": 0.9444761872291565
  },
  {
    "title": "First Circuit Adopts \"But-For\" Causation Standard For False Claims Act Cases Based On Anti-Kickback Statute Violations",
    "published": 1740359588,
    "day_prices": {
      "2025-02-24T14:30:00+00:00": 702.7050170898438,
      "2025-02-24T15:30:00+00:00": 716.0999755859375,
      "2025-02-24T16:30:00+00:00": 717.1719970703125,
      "2025-02-24T17:30:00+00:00": 715.9400024414062,
      "2025-02-24T18:30:00+00:00": 709.1998901367188,
      "2025-02-24T19:30:00+00:00": 710.6500244140625,
      "2025-02-24T20:30:00+00:00": 716.9600219726562
    },
    "sentiment": 0.9342505931854248
  },
  {
    "title": "American Century Ultra Fund Q4 2024 Commentary",
    "published": 1740149520,
    "day_prices": {
      "2025-02-21T14:30:00+00:00": 697.739990234375,
      "2025-02-21T15:30:00+00:00": 696.8200073242188,
      "2025-02-21T16:30:00+00:00": 698.364990234375,
      "2025-02-21T17:30:00+00:00": 698.4749755859375,
      "2025-02-21T18:30:00+00:00": 700.3400268554688,
      "2025-02-21T19:30:00+00:00": 701.81201171875,
      "2025-02-21T20:30:00+00:00": 701.7249755859375
    },
    "sentiment": 0.944507896900177
  },
  {
    "title": "False Claim Act Liability Under Anti-Kickback Statute Requires But-For Causation: First Circuit Narrows Liability In Growing Circuit Split",
    "published": 1740114609,
    "day_prices": {
      "2025-02-21T14:30:00+00:00": 697.739990234375,
      "2025-02-21T15:30:00+00:00": 696.8200073242188,
      "2025-02-21T16:30:00+00:00": 698.364990234375,
      "2025-02-21T17:30:00+00:00": 698.4749755859375,
      "2025-02-21T18:30:00+00:00": 700.3400268554688,
      "2025-02-21T19:30:00+00:00": 701.81201171875,
      "2025-02-21T20:30:00+00:00": 701.7249755859375
    },
    "sentiment": 0.8445479273796082
  },
  {
    "title": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "published": 1740069900,
    "day_prices": {
      "2025-02-20T14:30:00+00:00": 688.0499877929688,
      "2025-02-20T15:30:00+00:00": 697.0,
      "2025-02-20T16:30:00+00:00": 697.7587890625,
      "2025-02-20T17:30:00+00:00": 696.2000122070312,
      "2025-02-20T18:30:00+00:00": 694.4299926757812,
      "2025-02-20T19:30:00+00:00": 695.0999755859375,
      "2025-02-20T20:30:00+00:00": 693.3699951171875
    },
    "sentiment": 0.9394939541816711
  },
  {
    "title": "Allspring Disciplined U.S. Core Fund Q4 2024 Commentary",
    "published": 1740045900,
    "day_prices": {
      "2025-02-20T14:30:00+00:00": 688.0499877929688,
      "2025-02-20T15:30:00+00:00": 697.0,
      "2025-02-20T16:30:00+00:00": 697.7587890625,
      "2025-02-20T17:30:00+00:00": 696.2000122070312,
      "2025-02-20T18:30:00+00:00": 694.4299926757812,
      "2025-02-20T19:30:00+00:00": 695.0999755859375,
      "2025-02-20T20:30:00+00:00": 693.3699951171875
    },
    "sentiment": 0.9033114314079285
  },
  {
    "title": "Regeneron Pharmaceuticals - Dupixent sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid",
    "published": 1739965542,
    "day_prices": {
      "2025-02-19T14:30:00+00:00": 675.2899780273438,
      "2025-02-19T15:30:00+00:00": 686.2550048828125,
      "2025-02-19T16:30:00+00:00": 685.219970703125,
      "2025-02-19T17:30:00+00:00": 679.8499755859375,
      "2025-02-19T18:30:00+00:00": 682.0900268554688,
      "2025-02-19T19:30:00+00:00": 682.4149780273438,
      "2025-02-19T20:30:00+00:00": 685.1649780273438
    },
    "sentiment": 0.8389014601707458
  },
  {
    "title": "SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag",
    "published": 1739882400,
    "day_prices": {
      "2025-02-18T14:30:00+00:00": 679.6400146484375,
      "2025-02-18T15:30:00+00:00": 686.969970703125,
      "2025-02-18T16:30:00+00:00": 682.7249755859375,
      "2025-02-18T17:30:00+00:00": 677.739990234375,
      "2025-02-18T18:30:00+00:00": 679.7650146484375,
      "2025-02-18T19:30:00+00:00": 678.3790283203125,
      "2025-02-18T20:30:00+00:00": 679.8350219726562
    },
    "sentiment": 0.8196975588798523
  },
  {
    "title": "American Century Focused Dynamic Growth Fund Q4 2024 Commentary",
    "published": 1739866200,
    "day_prices": {
      "2025-02-18T14:30:00+00:00": 679.6400146484375,
      "2025-02-18T15:30:00+00:00": 686.969970703125,
      "2025-02-18T16:30:00+00:00": 682.7249755859375,
      "2025-02-18T17:30:00+00:00": 677.739990234375,
      "2025-02-18T18:30:00+00:00": 679.7650146484375,
      "2025-02-18T19:30:00+00:00": 678.3790283203125,
      "2025-02-18T20:30:00+00:00": 679.8350219726562
    },
    "sentiment": 0.8933947086334229
  },
  {
    "title": "Dupixent\u00ae (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)",
    "published": 1739858340,
    "day_prices": {
      "2025-02-18T14:30:00+00:00": 679.6400146484375,
      "2025-02-18T15:30:00+00:00": 686.969970703125,
      "2025-02-18T16:30:00+00:00": 682.7249755859375,
      "2025-02-18T17:30:00+00:00": 677.739990234375,
      "2025-02-18T18:30:00+00:00": 679.7650146484375,
      "2025-02-18T19:30:00+00:00": 678.3790283203125,
      "2025-02-18T20:30:00+00:00": 679.8350219726562
    },
    "sentiment": 0.862043023109436
  },
  {
    "title": "Alnylam Q4 Earnings Beat Estimates, Product Revenues Rise Y/Y",
    "published": 1739541540,
    "day_prices": {
      "2025-02-14T14:30:00+00:00": 678.2000122070312,
      "2025-02-14T15:30:00+00:00": 676.0,
      "2025-02-14T16:30:00+00:00": 672.52001953125,
      "2025-02-14T17:30:00+00:00": 673.8499755859375,
      "2025-02-14T18:30:00+00:00": 675.8699951171875,
      "2025-02-14T19:30:00+00:00": 679.1099853515625,
      "2025-02-14T20:30:00+00:00": 678.2650146484375
    },
    "sentiment": 0.9485195279121399
  },
  {
    "title": "Kiniksa Pharmaceuticals: Strong Improvement In Arcalyst Revenue, But Risks Remain",
    "published": 1739468968,
    "day_prices": {
      "2025-02-13T14:30:00+00:00": 665.4600219726562,
      "2025-02-13T15:30:00+00:00": 669.0,
      "2025-02-13T16:30:00+00:00": 673.3400268554688,
      "2025-02-13T17:30:00+00:00": 672.3099975585938,
      "2025-02-13T18:30:00+00:00": 669.7650146484375,
      "2025-02-13T19:30:00+00:00": 672.3800048828125,
      "2025-02-13T20:30:00+00:00": 671.5599975585938
    },
    "sentiment": 0.8951048851013184
  },
  {
    "title": "Janus Henderson Global Life Sciences Fund Q4 2024 Commentary",
    "published": 1739392800,
    "day_prices": {
      "2025-02-12T14:30:00+00:00": 659.9600219726562,
      "2025-02-12T15:30:00+00:00": 667.9299926757812,
      "2025-02-12T16:30:00+00:00": 660.3099975585938,
      "2025-02-12T17:30:00+00:00": 661.6900024414062,
      "2025-02-12T18:30:00+00:00": 657.8300170898438,
      "2025-02-12T19:30:00+00:00": 660.369873046875,
      "2025-02-12T20:30:00+00:00": 663.9450073242188
    },
    "sentiment": 0.9430727958679199
  },
  {
    "title": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "published": 1739291400,
    "day_prices": {
      "2025-02-11T14:30:00+00:00": 680.6300048828125,
      "2025-02-11T15:30:00+00:00": 672.5399780273438,
      "2025-02-11T16:30:00+00:00": 678.0499877929688,
      "2025-02-11T17:30:00+00:00": 671.1900024414062,
      "2025-02-11T18:30:00+00:00": 667.9099731445312,
      "2025-02-11T19:30:00+00:00": 671.5800170898438,
      "2025-02-11T20:30:00+00:00": 667.4500122070312
    },
    "sentiment": 0.9224351048469543
  },
  {
    "title": "Regeneron Gets New FDA Review of Linvoseltamab for Multiple Myeloma",
    "published": 1739259360,
    "day_prices": {
      "2025-02-11T14:30:00+00:00": 680.6300048828125,
      "2025-02-11T15:30:00+00:00": 672.5399780273438,
      "2025-02-11T16:30:00+00:00": 678.0499877929688,
      "2025-02-11T17:30:00+00:00": 671.1900024414062,
      "2025-02-11T18:30:00+00:00": 667.9099731445312,
      "2025-02-11T19:30:00+00:00": 671.5800170898438,
      "2025-02-11T20:30:00+00:00": 667.4500122070312
    },
    "sentiment": 0.7353188991546631
  },
  {
    "title": "Regeneron\u2019s macular oedema therapy shows promise in Phase III trial",
    "published": 1739204508,
    "day_prices": {
      "2025-02-10T14:30:00+00:00": 714.4500122070312,
      "2025-02-10T15:30:00+00:00": 705.8331909179688,
      "2025-02-10T16:30:00+00:00": 702.6199951171875,
      "2025-02-10T17:30:00+00:00": 705.3699951171875,
      "2025-02-10T18:30:00+00:00": 702.9500122070312,
      "2025-02-10T19:30:00+00:00": 699.6699829101562,
      "2025-02-10T20:30:00+00:00": 695.4600219726562
    },
    "sentiment": 0.9394028186798096
  },
  {
    "title": "Investing $1,000 in These 3 Beaten-Down Stocks Could Be a Brilliant Move",
    "published": 1739186100,
    "day_prices": {
      "2025-02-10T14:30:00+00:00": 714.4500122070312,
      "2025-02-10T15:30:00+00:00": 705.8331909179688,
      "2025-02-10T16:30:00+00:00": 702.6199951171875,
      "2025-02-10T17:30:00+00:00": 705.3699951171875,
      "2025-02-10T18:30:00+00:00": 702.9500122070312,
      "2025-02-10T19:30:00+00:00": 699.6699829101562,
      "2025-02-10T20:30:00+00:00": 695.4600219726562
    },
    "sentiment": 0.6466823816299438
  },
  {
    "title": "Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow",
    "published": 1739106130,
    "day_prices": {},
    "sentiment": 0.8645047545433044
  },
  {
    "title": "Three-Year Results for EYLEA HD\u00ae (aflibercept) Injection 8 mg in Patients with Wet Age-related Macular Degeneration Demonstrate Continued Durable Vision Gains and Anatomic Improvements with Extended Dosing Intervals",
    "published": 1739048100,
    "day_prices": {},
    "sentiment": 0.9568678736686707
  },
  {
    "title": "Fidelity Contrafund Q4 2024 Review",
    "published": 1738794900,
    "day_prices": {
      "2025-02-05T14:30:00+00:00": 708.7999877929688,
      "2025-02-05T15:30:00+00:00": 710.0700073242188,
      "2025-02-05T16:30:00+00:00": 710.6400146484375,
      "2025-02-05T17:30:00+00:00": 711.2139892578125,
      "2025-02-05T18:30:00+00:00": 712.2000122070312,
      "2025-02-05T19:30:00+00:00": 716.125,
      "2025-02-05T20:30:00+00:00": 719.348388671875
    },
    "sentiment": 0.934363603591919
  },
  {
    "title": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors despite daily gains",
    "published": 1738773720,
    "day_prices": {
      "2025-02-05T14:30:00+00:00": 708.7999877929688,
      "2025-02-05T15:30:00+00:00": 710.0700073242188,
      "2025-02-05T16:30:00+00:00": 710.6400146484375,
      "2025-02-05T17:30:00+00:00": 711.2139892578125,
      "2025-02-05T18:30:00+00:00": 712.2000122070312,
      "2025-02-05T19:30:00+00:00": 716.125,
      "2025-02-05T20:30:00+00:00": 719.348388671875
    },
    "sentiment": 0.8359856009483337
  },
  {
    "title": "Amgen obesity drug on hold; Regeneron sets first dividend",
    "published": 1738754880,
    "day_prices": {
      "2025-02-05T14:30:00+00:00": 708.7999877929688,
      "2025-02-05T15:30:00+00:00": 710.0700073242188,
      "2025-02-05T16:30:00+00:00": 710.6400146484375,
      "2025-02-05T17:30:00+00:00": 711.2139892578125,
      "2025-02-05T18:30:00+00:00": 712.2000122070312,
      "2025-02-05T19:30:00+00:00": 716.125,
      "2025-02-05T20:30:00+00:00": 719.348388671875
    },
    "sentiment": 0.8939981460571289
  },
  {
    "title": "Company News for Feb 5, 2025",
    "published": 1738752060,
    "day_prices": {
      "2025-02-05T14:30:00+00:00": 708.7999877929688,
      "2025-02-05T15:30:00+00:00": 710.0700073242188,
      "2025-02-05T16:30:00+00:00": 710.6400146484375,
      "2025-02-05T17:30:00+00:00": 711.2139892578125,
      "2025-02-05T18:30:00+00:00": 712.2000122070312,
      "2025-02-05T19:30:00+00:00": 716.125,
      "2025-02-05T20:30:00+00:00": 719.348388671875
    },
    "sentiment": 0.927605390548706
  },
  {
    "title": "Regeneron Presents An Opportunity After LIBTAYO Sales Growth Bolsters Earnings",
    "published": 1738741500,
    "day_prices": {
      "2025-02-05T14:30:00+00:00": 708.7999877929688,
      "2025-02-05T15:30:00+00:00": 710.0700073242188,
      "2025-02-05T16:30:00+00:00": 710.6400146484375,
      "2025-02-05T17:30:00+00:00": 711.2139892578125,
      "2025-02-05T18:30:00+00:00": 712.2000122070312,
      "2025-02-05T19:30:00+00:00": 716.125,
      "2025-02-05T20:30:00+00:00": 719.348388671875
    },
    "sentiment": 0.94891756772995
  },
  {
    "title": "Q4 2024 Regeneron Pharmaceuticals Inc Earnings Call",
    "published": 1738736721,
    "day_prices": {
      "2025-02-05T14:30:00+00:00": 708.7999877929688,
      "2025-02-05T15:30:00+00:00": 710.0700073242188,
      "2025-02-05T16:30:00+00:00": 710.6400146484375,
      "2025-02-05T17:30:00+00:00": 711.2139892578125,
      "2025-02-05T18:30:00+00:00": 712.2000122070312,
      "2025-02-05T19:30:00+00:00": 716.125,
      "2025-02-05T20:30:00+00:00": 719.348388671875
    },
    "sentiment": 0.7086933255195618
  },
  {
    "title": "Regeneron Pharmaceuticals Beats On Libtayo's Back, Unveils Dividend",
    "published": 1738703510,
    "day_prices": {
      "2025-02-04T14:30:00+00:00": 650.0,
      "2025-02-04T15:30:00+00:00": 687.0,
      "2025-02-04T16:30:00+00:00": 705.0,
      "2025-02-04T17:30:00+00:00": 696.1901245117188,
      "2025-02-04T18:30:00+00:00": 700.9500122070312,
      "2025-02-04T19:30:00+00:00": 706.4099731445312,
      "2025-02-04T20:30:00+00:00": 700.6599731445312
    },
    "sentiment": 0.8801659345626831
  },
  {
    "title": "MAIA\u2019s lung cancer therapy 99% more likely to improve OS over chemo alone",
    "published": 1738693238,
    "day_prices": {
      "2025-02-04T14:30:00+00:00": 650.0,
      "2025-02-04T15:30:00+00:00": 687.0,
      "2025-02-04T16:30:00+00:00": 705.0,
      "2025-02-04T17:30:00+00:00": 696.1901245117188,
      "2025-02-04T18:30:00+00:00": 700.9500122070312,
      "2025-02-04T19:30:00+00:00": 706.4099731445312,
      "2025-02-04T20:30:00+00:00": 700.6599731445312
    },
    "sentiment": 0.9084128737449646
  },
  {
    "title": "Is Regeneron Pharmaceuticals (REGN) the Best Cancer Stock to Buy According to Hedge Funds?",
    "published": 1738679738,
    "day_prices": {
      "2025-02-04T14:30:00+00:00": 650.0,
      "2025-02-04T15:30:00+00:00": 687.0,
      "2025-02-04T16:30:00+00:00": 705.0,
      "2025-02-04T17:30:00+00:00": 696.1901245117188,
      "2025-02-04T18:30:00+00:00": 700.9500122070312,
      "2025-02-04T19:30:00+00:00": 706.4099731445312,
      "2025-02-04T20:30:00+00:00": 700.6599731445312
    },
    "sentiment": 0.875864565372467
  },
  {
    "title": "Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics",
    "published": 1738679425,
    "day_prices": {
      "2025-02-04T14:30:00+00:00": 650.0,
      "2025-02-04T15:30:00+00:00": 687.0,
      "2025-02-04T16:30:00+00:00": 705.0,
      "2025-02-04T17:30:00+00:00": 696.1901245117188,
      "2025-02-04T18:30:00+00:00": 700.9500122070312,
      "2025-02-04T19:30:00+00:00": 706.4099731445312,
      "2025-02-04T20:30:00+00:00": 700.6599731445312
    },
    "sentiment": 0.8749426603317261
  },
  {
    "title": "Regeneron\u2019s earnings boosted by more than doubling of U.S. sales of blockbuster eye drug Eylea",
    "published": 1738674240,
    "day_prices": {
      "2025-02-04T14:30:00+00:00": 650.0,
      "2025-02-04T15:30:00+00:00": 687.0,
      "2025-02-04T16:30:00+00:00": 705.0,
      "2025-02-04T17:30:00+00:00": 696.1901245117188,
      "2025-02-04T18:30:00+00:00": 700.9500122070312,
      "2025-02-04T19:30:00+00:00": 706.4099731445312,
      "2025-02-04T20:30:00+00:00": 700.6599731445312
    },
    "sentiment": 0.9575777649879456
  },
  {
    "title": "Regeneron: Q4 Earnings Snapshot",
    "published": 1738670058,
    "day_prices": {
      "2025-02-04T14:30:00+00:00": 650.0,
      "2025-02-04T15:30:00+00:00": 687.0,
      "2025-02-04T16:30:00+00:00": 705.0,
      "2025-02-04T17:30:00+00:00": 696.1901245117188,
      "2025-02-04T18:30:00+00:00": 700.9500122070312,
      "2025-02-04T19:30:00+00:00": 706.4099731445312,
      "2025-02-04T20:30:00+00:00": 700.6599731445312
    },
    "sentiment": 0.6524545550346375
  },
  {
    "title": "Regeneron Pharmaceuticals, Inc. (REGN) Q4 2024 Earnings Call Transcript",
    "published": 1738668856,
    "day_prices": {
      "2025-02-04T14:30:00+00:00": 650.0,
      "2025-02-04T15:30:00+00:00": 687.0,
      "2025-02-04T16:30:00+00:00": 705.0,
      "2025-02-04T17:30:00+00:00": 696.1901245117188,
      "2025-02-04T18:30:00+00:00": 700.9500122070312,
      "2025-02-04T19:30:00+00:00": 706.4099731445312,
      "2025-02-04T20:30:00+00:00": 700.6599731445312
    },
    "sentiment": 0.9010696411132812
  },
  {
    "title": "REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm",
    "published": 1738656725,
    "day_prices": {
      "2025-02-04T14:30:00+00:00": 650.0,
      "2025-02-04T15:30:00+00:00": 687.0,
      "2025-02-04T16:30:00+00:00": 705.0,
      "2025-02-04T17:30:00+00:00": 696.1901245117188,
      "2025-02-04T18:30:00+00:00": 700.9500122070312,
      "2025-02-04T19:30:00+00:00": 706.4099731445312,
      "2025-02-04T20:30:00+00:00": 700.6599731445312
    },
    "sentiment": 0.8076428174972534
  },
  {
    "title": "Regeneron Launches Dividend Program, Boost Stock Buybacks",
    "published": 1738653074,
    "day_prices": {
      "2025-02-04T14:30:00+00:00": 650.0,
      "2025-02-04T15:30:00+00:00": 687.0,
      "2025-02-04T16:30:00+00:00": 705.0,
      "2025-02-04T17:30:00+00:00": 696.1901245117188,
      "2025-02-04T18:30:00+00:00": 700.9500122070312,
      "2025-02-04T19:30:00+00:00": 706.4099731445312,
      "2025-02-04T20:30:00+00:00": 700.6599731445312
    },
    "sentiment": 0.7956432104110718
  },
  {
    "title": "Alphabet results lead busy day of earnings",
    "published": 1738648510,
    "day_prices": {
      "2025-02-04T14:30:00+00:00": 650.0,
      "2025-02-04T15:30:00+00:00": 687.0,
      "2025-02-04T16:30:00+00:00": 705.0,
      "2025-02-04T17:30:00+00:00": 696.1901245117188,
      "2025-02-04T18:30:00+00:00": 700.9500122070312,
      "2025-02-04T19:30:00+00:00": 706.4099731445312,
      "2025-02-04T20:30:00+00:00": 700.6599731445312
    },
    "sentiment": 0.7385496497154236
  },
  {
    "title": "Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN",
    "published": 1738561579,
    "day_prices": {
      "2025-02-03T14:30:00+00:00": 668.5,
      "2025-02-03T15:30:00+00:00": 670.239990234375,
      "2025-02-03T16:30:00+00:00": 668.9500122070312,
      "2025-02-03T17:30:00+00:00": 669.1799926757812,
      "2025-02-03T18:30:00+00:00": 666.7999877929688,
      "2025-02-03T19:30:00+00:00": 667.1300048828125,
      "2025-02-03T20:30:00+00:00": 668.4149780273438
    },
    "sentiment": 0.9396686553955078
  },
  {
    "title": "abrdn Life Sciences Investors Q4 2024 Commentary",
    "published": 1743306600,
    "day_prices": {},
    "sentiment": 0.9462534785270691
  },
  {
    "title": "AbbVie Vs. Sanofi: Which Is The Better Investment Right Now",
    "published": 1743155082,
    "day_prices": {
      "2025-03-28T13:30:00+00:00": 638.010009765625,
      "2025-03-28T14:30:00+00:00": 633.6500244140625,
      "2025-03-28T15:30:00+00:00": 638.1900024414062,
      "2025-03-28T16:30:00+00:00": 641.5,
      "2025-03-28T17:30:00+00:00": 640.412109375,
      "2025-03-28T18:30:00+00:00": 639.0999755859375,
      "2025-03-28T19:30:00+00:00": 639.47998046875
    },
    "sentiment": 0.8270342350006104
  },
  {
    "title": "Corvus Pharmaceuticals: Now At Cruising Altitude",
    "published": 1743154195,
    "day_prices": {
      "2025-03-28T13:30:00+00:00": 638.010009765625,
      "2025-03-28T14:30:00+00:00": 633.6500244140625,
      "2025-03-28T15:30:00+00:00": 638.1900024414062,
      "2025-03-28T16:30:00+00:00": 641.5,
      "2025-03-28T17:30:00+00:00": 640.412109375,
      "2025-03-28T18:30:00+00:00": 639.0999755859375,
      "2025-03-28T19:30:00+00:00": 639.47998046875
    },
    "sentiment": 0.819064199924469
  },
  {
    "title": "Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication",
    "published": 1743143052,
    "day_prices": {
      "2025-03-28T13:30:00+00:00": 638.010009765625,
      "2025-03-28T14:30:00+00:00": 633.6500244140625,
      "2025-03-28T15:30:00+00:00": 638.1900024414062,
      "2025-03-28T16:30:00+00:00": 641.5,
      "2025-03-28T17:30:00+00:00": 640.412109375,
      "2025-03-28T18:30:00+00:00": 639.0999755859375,
      "2025-03-28T19:30:00+00:00": 639.47998046875
    },
    "sentiment": 0.905643880367279
  },
  {
    "title": "Putnam Large Cap Value Fund Q4 2024 Commentary",
    "published": 1743119100,
    "day_prices": {
      "2025-03-27T13:30:00+00:00": 641.2100219726562,
      "2025-03-27T14:30:00+00:00": 637.0,
      "2025-03-27T15:30:00+00:00": 632.3800048828125,
      "2025-03-27T16:30:00+00:00": 633.8599853515625,
      "2025-03-27T17:30:00+00:00": 630.7100219726562,
      "2025-03-27T18:30:00+00:00": 635.47998046875,
      "2025-03-27T19:30:00+00:00": 639.780029296875
    },
    "sentiment": 0.8833929896354675
  },
  {
    "title": "Franklin Biotechnology Discovery Fund Q4 2024 Commentary",
    "published": 1743060600,
    "day_prices": {
      "2025-03-27T13:30:00+00:00": 641.2100219726562,
      "2025-03-27T14:30:00+00:00": 637.0,
      "2025-03-27T15:30:00+00:00": 632.3800048828125,
      "2025-03-27T16:30:00+00:00": 633.8599853515625,
      "2025-03-27T17:30:00+00:00": 630.7100219726562,
      "2025-03-27T18:30:00+00:00": 635.47998046875,
      "2025-03-27T19:30:00+00:00": 639.780029296875
    },
    "sentiment": 0.9198147058486938
  },
  {
    "title": "Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025",
    "published": 1742933100,
    "day_prices": {
      "2025-03-25T13:30:00+00:00": 662.4500122070312,
      "2025-03-25T14:30:00+00:00": 653.739990234375,
      "2025-03-25T15:30:00+00:00": 654.1900024414062,
      "2025-03-25T16:30:00+00:00": 650.4000244140625,
      "2025-03-25T17:30:00+00:00": 647.0,
      "2025-03-25T18:30:00+00:00": 640.1824951171875,
      "2025-03-25T19:30:00+00:00": 636.030029296875
    },
    "sentiment": 0.9493489861488342
  },
  {
    "title": "UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study",
    "published": 1742917860,
    "day_prices": {
      "2025-03-25T13:30:00+00:00": 662.4500122070312,
      "2025-03-25T14:30:00+00:00": 653.739990234375,
      "2025-03-25T15:30:00+00:00": 654.1900024414062,
      "2025-03-25T16:30:00+00:00": 650.4000244140625,
      "2025-03-25T17:30:00+00:00": 647.0,
      "2025-03-25T18:30:00+00:00": 640.1824951171875,
      "2025-03-25T19:30:00+00:00": 636.030029296875
    },
    "sentiment": 0.9713146090507507
  },
  {
    "title": "3 Reasons to Sell REGN and 1 Stock to Buy Instead",
    "published": 1742547998,
    "day_prices": {
      "2025-03-21T13:30:00+00:00": 658.0,
      "2025-03-21T14:30:00+00:00": 657.9849853515625,
      "2025-03-21T15:30:00+00:00": 655.4199829101562,
      "2025-03-21T16:30:00+00:00": 659.47998046875,
      "2025-03-21T17:30:00+00:00": 657.5748901367188,
      "2025-03-21T18:30:00+00:00": 656.0,
      "2025-03-21T19:30:00+00:00": 651.6799926757812
    },
    "sentiment": 0.9467926025390625
  },
  {
    "title": "Invesco American Franchise Fund Q4 2024 Commentary",
    "published": 1742462400,
    "day_prices": {
      "2025-03-20T13:30:00+00:00": 670.0,
      "2025-03-20T14:30:00+00:00": 673.0,
      "2025-03-20T15:30:00+00:00": 664.3300170898438,
      "2025-03-20T16:30:00+00:00": 666.6699829101562,
      "2025-03-20T17:30:00+00:00": 664.489990234375,
      "2025-03-20T18:30:00+00:00": 665.02001953125,
      "2025-03-20T19:30:00+00:00": 662.7750244140625
    },
    "sentiment": 0.9400650858879089
  },
  {
    "title": "Invesco Health Care Fund Q4 2024 Commentary",
    "published": 1742461500,
    "day_prices": {
      "2025-03-20T13:30:00+00:00": 670.0,
      "2025-03-20T14:30:00+00:00": 673.0,
      "2025-03-20T15:30:00+00:00": 664.3300170898438,
      "2025-03-20T16:30:00+00:00": 666.6699829101562,
      "2025-03-20T17:30:00+00:00": 664.489990234375,
      "2025-03-20T18:30:00+00:00": 665.02001953125,
      "2025-03-20T19:30:00+00:00": 662.7750244140625
    },
    "sentiment": 0.944513738155365
  },
  {
    "title": "Regeneron Pharmaceuticals (REGN): Among the Best Biotech Stocks to Buy According to Billionaires",
    "published": 1742290681,
    "day_prices": {
      "2025-03-18T13:30:00+00:00": 678.0,
      "2025-03-18T14:30:00+00:00": 672.0,
      "2025-03-18T15:30:00+00:00": 672.3900146484375,
      "2025-03-18T16:30:00+00:00": 670.260009765625,
      "2025-03-18T17:30:00+00:00": 669.97998046875,
      "2025-03-18T18:30:00+00:00": 671.0599975585938,
      "2025-03-18T19:30:00+00:00": 670.0050048828125
    },
    "sentiment": 0.7628839612007141
  },
  {
    "title": "Jim Cramer Wants You to \u2018Own\u2019 Regeneron Pharmaceuticals (REGN) Shares",
    "published": 1742263623,
    "day_prices": {
      "2025-03-18T13:30:00+00:00": 678.0,
      "2025-03-18T14:30:00+00:00": 672.0,
      "2025-03-18T15:30:00+00:00": 672.3900146484375,
      "2025-03-18T16:30:00+00:00": 670.260009765625,
      "2025-03-18T17:30:00+00:00": 669.97998046875,
      "2025-03-18T18:30:00+00:00": 671.0599975585938,
      "2025-03-18T19:30:00+00:00": 670.0050048828125
    },
    "sentiment": 0.9432457685470581
  },
  {
    "title": "Regeneron Pharmaceuticals (NasdaqGS:REGN) Shares Dip 1% Despite Positive Dupixent Trial Results",
    "published": 1742232152,
    "day_prices": {
      "2025-03-17T13:30:00+00:00": 668.1500244140625,
      "2025-03-17T14:30:00+00:00": 669.239990234375,
      "2025-03-17T15:30:00+00:00": 666.8599853515625,
      "2025-03-17T16:30:00+00:00": 669.5020141601562,
      "2025-03-17T17:30:00+00:00": 672.0,
      "2025-03-17T18:30:00+00:00": 675.6699829101562,
      "2025-03-17T19:30:00+00:00": 676.7949829101562
    },
    "sentiment": 0.5026289820671082
  },
  {
    "title": "Regeneron Pharmaceuticals Inc. stock underperforms Friday when compared to competitors",
    "published": 1741970460,
    "day_prices": {
      "2025-03-14T13:30:00+00:00": 680.6099853515625,
      "2025-03-14T14:30:00+00:00": 680.2050170898438,
      "2025-03-14T15:30:00+00:00": 671.2000122070312,
      "2025-03-14T16:30:00+00:00": 667.594970703125,
      "2025-03-14T17:30:00+00:00": 663.0999755859375,
      "2025-03-14T18:30:00+00:00": 665.0,
      "2025-03-14T19:30:00+00:00": 667.8200073242188
    },
    "sentiment": 0.9191316962242126
  },
  {
    "title": "Regeneron Pharmaceuticals Has Lost Its Way, But Can It Find It Again?",
    "published": 1741945228,
    "day_prices": {
      "2025-03-14T13:30:00+00:00": 680.6099853515625,
      "2025-03-14T14:30:00+00:00": 680.2050170898438,
      "2025-03-14T15:30:00+00:00": 671.2000122070312,
      "2025-03-14T16:30:00+00:00": 667.594970703125,
      "2025-03-14T17:30:00+00:00": 663.0999755859375,
      "2025-03-14T18:30:00+00:00": 665.0,
      "2025-03-14T19:30:00+00:00": 667.8200073242188
    },
    "sentiment": 0.8736091256141663
  },
  {
    "title": "Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors",
    "published": 1741797720,
    "day_prices": {
      "2025-03-12T13:30:00+00:00": 709.9400024414062,
      "2025-03-12T14:30:00+00:00": 701.9500122070312,
      "2025-03-12T15:30:00+00:00": 688.1300048828125,
      "2025-03-12T16:30:00+00:00": 695.0,
      "2025-03-12T17:30:00+00:00": 693.0850219726562,
      "2025-03-12T18:30:00+00:00": 688.9349975585938,
      "2025-03-12T19:30:00+00:00": 692.7550048828125
    },
    "sentiment": 0.9294024705886841
  },
  {
    "title": "Invesco Summit Fund Q4 2024 Commentary",
    "published": 1741777200,
    "day_prices": {
      "2025-03-12T13:30:00+00:00": 709.9400024414062,
      "2025-03-12T14:30:00+00:00": 701.9500122070312,
      "2025-03-12T15:30:00+00:00": 688.1300048828125,
      "2025-03-12T16:30:00+00:00": 695.0,
      "2025-03-12T17:30:00+00:00": 693.0850219726562,
      "2025-03-12T18:30:00+00:00": 688.9349975585938,
      "2025-03-12T19:30:00+00:00": 692.7550048828125
    },
    "sentiment": 0.9383469820022583
  },
  {
    "title": "Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem",
    "published": 1741743120,
    "day_prices": {
      "2025-03-12T13:30:00+00:00": 709.9400024414062,
      "2025-03-12T14:30:00+00:00": 701.9500122070312,
      "2025-03-12T15:30:00+00:00": 688.1300048828125,
      "2025-03-12T16:30:00+00:00": 695.0,
      "2025-03-12T17:30:00+00:00": 693.0850219726562,
      "2025-03-12T18:30:00+00:00": 688.9349975585938,
      "2025-03-12T19:30:00+00:00": 692.7550048828125
    },
    "sentiment": 0.8588088750839233
  },
  {
    "title": "Regeneron Pharmaceuticals, Inc. (REGN): Hedge Funds Are Bullish On This Oversold Blue Chip Stock Now",
    "published": 1741649368,
    "day_prices": {
      "2025-03-10T13:30:00+00:00": 710.010009765625,
      "2025-03-10T14:30:00+00:00": 731.5,
      "2025-03-10T15:30:00+00:00": 745.2775268554688,
      "2025-03-10T16:30:00+00:00": 744.0,
      "2025-03-10T17:30:00+00:00": 740.8599853515625,
      "2025-03-10T18:30:00+00:00": 739.6300048828125,
      "2025-03-10T19:30:00+00:00": 744.405029296875
    },
    "sentiment": 0.6303601861000061
  },
  {
    "title": "REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm",
    "published": 1741625163,
    "day_prices": {
      "2025-03-10T13:30:00+00:00": 710.010009765625,
      "2025-03-10T14:30:00+00:00": 731.5,
      "2025-03-10T15:30:00+00:00": 745.2775268554688,
      "2025-03-10T16:30:00+00:00": 744.0,
      "2025-03-10T17:30:00+00:00": 740.8599853515625,
      "2025-03-10T18:30:00+00:00": 739.6300048828125,
      "2025-03-10T19:30:00+00:00": 744.405029296875
    },
    "sentiment": 0.8076428174972534
  },
  {
    "title": "REGN LAWSUIT ALERT: The Gross Law Firm Notifies Regeneron Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline",
    "published": 1741585582,
    "day_prices": {
      "2025-03-10T13:30:00+00:00": 710.010009765625,
      "2025-03-10T14:30:00+00:00": 731.5,
      "2025-03-10T15:30:00+00:00": 745.2775268554688,
      "2025-03-10T16:30:00+00:00": 744.0,
      "2025-03-10T17:30:00+00:00": 740.8599853515625,
      "2025-03-10T18:30:00+00:00": 739.6300048828125,
      "2025-03-10T19:30:00+00:00": 744.405029296875
    },
    "sentiment": 0.7656306624412537
  },
  {
    "title": "Dupixent\u00ae (dupilumab) Late-Breaking Positive Pivotal Data in Bullous Pemphigoid Presented at AAD",
    "published": 1741456800,
    "day_prices": {},
    "sentiment": 0.6090592741966248
  },
  {
    "title": "Regeneron Pharmaceuticals, Inc. and Sanofi Presents Positive Results from the Pivotal ADEPT Phase 2/3 trial",
    "published": 1741438800,
    "day_prices": {},
    "sentiment": 0.954128623008728
  },
  {
    "title": "REGN Deadline: REGN Investors with Losses in Excess of $100K Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit",
    "published": 1741361764,
    "day_prices": {
      "2025-03-07T14:30:00+00:00": 698.6300048828125,
      "2025-03-07T15:30:00+00:00": 718.7899780273438,
      "2025-03-07T16:30:00+00:00": 719.094970703125,
      "2025-03-07T17:30:00+00:00": 722.5800170898438,
      "2025-03-07T18:30:00+00:00": 728.219970703125,
      "2025-03-07T19:30:00+00:00": 717.1300048828125,
      "2025-03-07T20:30:00+00:00": 712.4450073242188
    },
    "sentiment": 0.7900741696357727
  },
  {
    "title": "The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals",
    "published": 1741334340,
    "day_prices": {
      "2025-03-07T14:30:00+00:00": 698.6300048828125,
      "2025-03-07T15:30:00+00:00": 718.7899780273438,
      "2025-03-07T16:30:00+00:00": 719.094970703125,
      "2025-03-07T17:30:00+00:00": 722.5800170898438,
      "2025-03-07T18:30:00+00:00": 728.219970703125,
      "2025-03-07T19:30:00+00:00": 717.1300048828125,
      "2025-03-07T20:30:00+00:00": 712.4450073242188
    },
    "sentiment": 0.944832980632782
  },
  {
    "title": "Fidelity Fund Q4 2024 Review",
    "published": 1741267020,
    "day_prices": {
      "2025-03-06T14:30:00+00:00": 683.0999755859375,
      "2025-03-06T15:30:00+00:00": 685.4550170898438,
      "2025-03-06T16:30:00+00:00": 689.3900146484375,
      "2025-03-06T17:30:00+00:00": 688.9199829101562,
      "2025-03-06T18:30:00+00:00": 692.9099731445312,
      "2025-03-06T19:30:00+00:00": 698.3699951171875,
      "2025-03-06T20:30:00+00:00": 698.9000244140625
    },
    "sentiment": 0.9469390511512756
  },
  {
    "title": "Ocular Therapeutix: Axpaxli's Dual Trial Strategy And Blockbuster Potential",
    "published": 1741259703,
    "day_prices": {
      "2025-03-06T14:30:00+00:00": 683.0999755859375,
      "2025-03-06T15:30:00+00:00": 685.4550170898438,
      "2025-03-06T16:30:00+00:00": 689.3900146484375,
      "2025-03-06T17:30:00+00:00": 688.9199829101562,
      "2025-03-06T18:30:00+00:00": 692.9099731445312,
      "2025-03-06T19:30:00+00:00": 698.3699951171875,
      "2025-03-06T20:30:00+00:00": 698.9000244140625
    },
    "sentiment": 0.820453941822052
  },
  {
    "title": "SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals",
    "published": 1741172645,
    "day_prices": {
      "2025-03-05T14:30:00+00:00": 673.97998046875,
      "2025-03-05T15:30:00+00:00": 678.97998046875,
      "2025-03-05T16:30:00+00:00": 676.219970703125,
      "2025-03-05T17:30:00+00:00": 679.3300170898438,
      "2025-03-05T18:30:00+00:00": 682.8599853515625,
      "2025-03-05T19:30:00+00:00": 690.989990234375,
      "2025-03-05T20:30:00+00:00": 688.6300048828125
    },
    "sentiment": 0.7528876066207886
  },
  {
    "title": "Regeneron Pharmaceuticals, Inc. (REGN) TD Cowen 45th Annual Health Care Conference (Transcript)",
    "published": 1741097493,
    "day_prices": {
      "2025-03-04T14:30:00+00:00": 688.47998046875,
      "2025-03-04T15:30:00+00:00": 693.030029296875,
      "2025-03-04T16:30:00+00:00": 689.72998046875,
      "2025-03-04T17:30:00+00:00": 686.375,
      "2025-03-04T18:30:00+00:00": 681.489990234375,
      "2025-03-04T19:30:00+00:00": 680.5549926757812,
      "2025-03-04T20:30:00+00:00": 683.4600219726562
    },
    "sentiment": 0.9286248087882996
  },
  {
    "title": "Contact Levi & Korsinsky by March 10, 2025 Deadline to Join Class Action Against Regeneron Pharmaceuticals, Inc.(REGN)",
    "published": 1741067181,
    "day_prices": {
      "2025-03-04T14:30:00+00:00": 688.47998046875,
      "2025-03-04T15:30:00+00:00": 693.030029296875,
      "2025-03-04T16:30:00+00:00": 689.72998046875,
      "2025-03-04T17:30:00+00:00": 686.375,
      "2025-03-04T18:30:00+00:00": 681.489990234375,
      "2025-03-04T19:30:00+00:00": 680.5549926757812,
      "2025-03-04T20:30:00+00:00": 683.4600219726562
    },
    "sentiment": 0.9143860936164856
  },
  {
    "title": "Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors",
    "published": 1741020120,
    "day_prices": {
      "2025-03-03T14:30:00+00:00": 695.2999877929688,
      "2025-03-03T15:30:00+00:00": 687.9650268554688,
      "2025-03-03T16:30:00+00:00": 686.3099975585938,
      "2025-03-03T17:30:00+00:00": 690.6856079101562,
      "2025-03-03T18:30:00+00:00": 688.2852172851562,
      "2025-03-03T19:30:00+00:00": 689.0449829101562,
      "2025-03-03T20:30:00+00:00": 685.219970703125
    },
    "sentiment": 0.9316853284835815
  },
  {
    "title": "Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact The Gross Law Firm Before March 10, 2025 to Discuss Your Rights - REGN",
    "published": 1740980781,
    "day_prices": {
      "2025-03-03T14:30:00+00:00": 695.2999877929688,
      "2025-03-03T15:30:00+00:00": 687.9650268554688,
      "2025-03-03T16:30:00+00:00": 686.3099975585938,
      "2025-03-03T17:30:00+00:00": 690.6856079101562,
      "2025-03-03T18:30:00+00:00": 688.2852172851562,
      "2025-03-03T19:30:00+00:00": 689.0449829101562,
      "2025-03-03T20:30:00+00:00": 685.219970703125
    },
    "sentiment": 0.9396686553955078
  },
  {
    "title": "Invest In A New Biotech Bull Market With XBI And IBB",
    "published": 1740904387,
    "day_prices": {},
    "sentiment": 0.7907221913337708
  }
]